An interventional study of Tamsulosin and Placebo in Multiple Sclerosis, Dysuria and Lower Urinary Tract Symptoms, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes — 1 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Centre Hospitalier Universitaire de Nīmes.
Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 11th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes is open now, in 1 country.
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 81 across the 6 interventional studies, 200 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
2 of the studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860947Centre Hospitalier Universitaire de NīmesAssessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients | 2027-03 |
| NCT03981003Centre Hospitalier Universitaire de NīmesSerum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple sclerosis (MS) is the leading non-traumatic cause of severe acquired disability in young people. The disease is defined by relapses, which can affect all neurological functions depending on the location of the new inflammatory lesion(s). The disease can thus manifest itself through bladder and bowel disorders (BWS), which affect approximately 80% of MS patients in all stages. Lower urinary tract dysfunction has a significant negative impact on the quality of life of patients and places a significant burden on the healthcare system in terms of resource allocation. In addition, there is a risk of long-term chronic renal failure, an infectious risk (recurrent cystitis and/or pyelonephritis, sometimes life-threatening) and a lithiasis risk.
The most frequently observed urinary symptoms are: urinary frequency, urgency with or without urinary incontinence, dysuria and chronic retention of urine. These disorders most often combine bladder hyperactivity and dysuria. This dysuria may be responsible for recurrent urinary tract infections, lithiasis, alteration of renal function.
The only therapeutic class currently used to treat dysuria in MS is alpha-blockers. Tamsulosin, alfusozin and doxazosin induce relaxation of the urethral smooth sphincter and prostatic urethral muscle fibers, facilitating the removal of subvesical obstruction and bladder emptying.
The study investigators hypothesize that treatment with tamsulosin 0.4 mg daily in adult MS patients with dysuria will result in symptom improvement as assessed by the International Prostate Symptom Score (IPSS) and Urinary Symptom Profile (USP) scores, a decrease in post-void residual, and an improvement in urine flow and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tamsulosin
Drug: Placebo
One 0.4mg Tamsulosin capsule taken per day for 30 days
one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
Urinary symptoms between groups
Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35
Time frame: Start of first intervention phase (Day 0)
Urinary symptoms between groups
Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35
Time frame: End of first intervention phase (Day 30)
Urinary symptoms between groups
Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35
Time frame: Start of first intervention phase (Day 60)
Urinary symptoms between groups
Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35
Time frame: End of first intervention phase (Day 90)
Urinary symptoms between groups
Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39
Time frame: Start of first intervention phase (Day 0)
Urinary symptoms between groups
Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39
Time frame: End of first intervention phase (Day 30)
Urinary symptoms between groups
Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39
Time frame: Start of first intervention phase (Day 60)
Urinary symptoms between groups
Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39
Time frame: End of first intervention phase (Day 90)
Post-mictional residue between groups
ml, measured with BladderScan
Time frame: Start of first intervention phase (Day 0)
Post-mictional residue between groups
ml, measured with BladderScan
Time frame: End of first intervention phase (Day 30)
Post-mictional residue between groups
ml, measured with BladderScan
Time frame: Start of first intervention phase (Day 60)
Post-mictional residue between groups
ml, measured with BladderScan
Time frame: End of first intervention phase (Day 90)
Maximum urine flow rate between groups
ml/s
Time frame: Start of first intervention phase (Day 0)
Maximum urine flow rate between groups
ml/s
Time frame: End of first intervention phase (Day 30)
Maximum urine flow rate between groups
ml/s
Time frame: Start of first intervention phase (Day 60)
Maximum urine flow rate between groups
ml/s
Time frame: End of first intervention phase (Day 90)
Quality of life linked to urinary dysfunction between groups
Qualiveen-30 questionnaire; score 0-4
Time frame: Start of first intervention phase (Day 0)
Quality of life linked to urinary dysfunction between groups
Qualiveen-30 questionnaire; score 0-4
Time frame: End of first intervention phase (Day 30)
Quality of life linked to urinary dysfunction between groups
Qualiveen-30 questionnaire; score 0-4
Time frame: Start of first intervention phase (Day 60)
Quality of life linked to urinary dysfunction between groups
Qualiveen-30 questionnaire; score 0-4
Time frame: End of first intervention phase (Day 90)
Quality of life between groups
EQ-5D questionnaire; score 0-100
Time frame: Start of first intervention phase (Day 0)
Quality of life between groups
EQ-5D questionnaire; score 0-100
Time frame: End of first intervention phase (Day 30)
Quality of life between groups
EQ-5D questionnaire; score 0-100
Time frame: Start of first intervention phase (Day 60)
Quality of life between groups
EQ-5D questionnaire; score 0-100
Time frame: End of first intervention phase (Day 90)
Fatigue between groups
Modified Fatigue Impact Scale; score 0-84
Time frame: Start of first intervention phase (Day 0)
Fatigue between groups
Modified Fatigue Impact Scale; score 0-84
Time frame: End of first intervention phase (Day 30)
Fatigue between groups
Modified Fatigue Impact Scale; score 0-84
Time frame: Start of first intervention phase (Day 60)
Fatigue between groups
Modified Fatigue Impact Scale; score 0-84
Time frame: End of first intervention phase (Day 90)
Drug safety
Yes/no occurence of the following adverse events: headache, asthenia, gastrointestinal disorders, orthostatic hypotension
Time frame: End of first intervention phase (Day 30)
Drug safety
Yes/no occurence of the following adverse events: headache, asthenia, gastrointestinal disorders, orthostatic hypotension
Time frame: End of first intervention phase (Day 90)
Started Oct 2022 (actual). Primary completion is estimated for Mar 2026, 41 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 41 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin
Centre Hospitalier Universitaire de Nīmes →